Back نيبيفولول Arabic Nebivolol BS Nebivolol German Νεμπιβολόλη Greek Nebivolol Spanish نبیوولول Persian Nebivololi Finnish Nébivolol French Nebivolol Hungarian Nebivololo Italian

Nebivolol

Nebivolol
Clinical data
Trade namesNebilet, Bystolic, others
Other namesNarbivolol, Nebivolol, Nebivololum[1]
AHFS/Drugs.comMonograph
MedlinePlusa608029
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding98%
MetabolismLiver (CYP2D6-mediated)
Elimination half-life12-19 hours[2][3][4]
ExcretionKidney and fecal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25F2NO4
Molar mass405.442 g·mol−1
3D model (JSmol)
  • Fc4cc1c(OC(CC1)C(O)CNCC(O)C3Oc2ccc(F)cc2CC3)cc4
  • InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2 checkY
  • Key:KOHIRBRYDXPAMZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)
Ebivol (Nebivolol) tablets

Nebivolol is a beta blocker used to treat high blood pressure and heart failure.[5] As with other β-blockers, it is generally a less preferred treatment for high blood pressure.[6] It may be used by itself or with other blood pressure medication.[6] It is taken by mouth.[6]

Common side effects include dizziness, feeling tired, nausea, and headaches.[6] Serious side effects may include heart failure and bronchospasm.[6] Its use in pregnancy and breastfeeding is not recommended.[5][7] It works by blocking β1-adrenergic receptors in the heart and dilating blood vessels.[6][8]

Nebivolol was patented in 1983 and came into medical use in 1997.[9] It is available as a generic medication in the United Kingdom.[5] In 2022, it was the 173rd most commonly prescribed medication in the United States, with more than 3 million prescriptions.[10][11]

  1. ^ "Nebivolol". go.drugbank.com. Retrieved 17 August 2022.
  2. ^ "Drugs@FDA: FDA-Approved Drugs Nebivolol - ALLERGAN" (PDF). accessdata.fda.gov. Retrieved 17 August 2022.
  3. ^ Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM (September 2017). "Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data". Journal of Hypertension. 35 (9): 1758–1767. doi:10.1097/HJH.0000000000001412. PMC 5548499. PMID 28509722.
  4. ^ "DrugBank Nebivolol". go.drugbank.com. Retrieved 17 August 2022.
  5. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 154. ISBN 9780857113382.
  6. ^ a b c d e f "Nebivolol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  7. ^ "Nebivolol Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  8. ^ de Boer RA, Voors AA, van Veldhuisen DJ (July 2007). "Nebivolol: third-generation beta-blockade". Expert Opinion on Pharmacotherapy. 8 (10): 1539–1550. doi:10.1517/14656566.8.10.1539. PMID 17661735. S2CID 24186687.
  9. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 462. ISBN 9783527607495.
  10. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  11. ^ "Nebivolol Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

Developed by StudentB